Hepatocellular Carcinoma Clinical Trials

288 recruiting

Hepatocellular Carcinoma Trials at a Glance

511 actively recruiting trials for hepatocellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 196 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Seoul. Lead sponsors running hepatocellular carcinoma studies include Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University, and Zhongda Hospital.

Browse hepatocellular carcinoma trials by phase

Treatments under study

About Hepatocellular Carcinoma Clinical Trials

Looking for clinical trials for Hepatocellular Carcinoma? There are currently 288 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatocellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 511 trials

Recruiting
Phase 1

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 2

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Hepatocellular CarcinomaHCC
University of California, Irvine35 enrolled1 locationNCT04472767
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma
University of Miami30 enrolled1 locationNCT06902246
Recruiting
Phase 2

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

Hepatocellular CarcinomaBCLC Stage C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute184 enrolled1 locationNCT07274774
Recruiting
Not Applicable

Computer Guided Microwave Liver Ablation

Hepatocellular Carcinoma (HCC)
NE Scientific INC84 enrolled2 locationsNCT07226869
Recruiting
Phase 2

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Hepatocellular Carcinoma (HCC)TACETIPS+2 more
First Affiliated Hospital, Sun Yat-Sen University206 enrolled1 locationNCT07322848
Recruiting
Phase 1

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)
University of Hawaii15 enrolled2 locationsNCT07075120
Recruiting
Phase 1

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

Hepatocellular Carcinoma
University of California, San Diego20 enrolled1 locationNCT06710223
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1Phase 2

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated193 enrolled21 locationsNCT05440708
Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Lung Cancer, Hepatocellular Carcinoma
Hoffmann-La Roche700 enrolled88 locationsNCT07284121
Recruiting
Phase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled4 locationsNCT07175441
Recruiting
Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH104 enrolled2 locationsNCT07219459
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT07422753
Recruiting

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Advanced Hepatocellular Carcinoma (HCC)
Fudan University150 enrolled1 locationNCT07147101
Recruiting
Phase 2

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490